528113
PI 3-Kβ Inhibitor VI, TGX-221 - CAS 663619-89-4 - Calbiochem
The PI 3-Kβ Inhibitor VI, TGX-221, also referenced under CAS 663619-89-4, controls the biological activity of PI 3-Kβ. This small molecule/inhibitor is primarily used for Cell Signaling applications.
别名:
PI 3-Kβ Inhibitor VI, TGX-221 - CAS 663619-89-4 - Calbiochem, (±)-7-Methyl-2-(morpholin-4-yl)-9-(1-phenylaminoethyl)-pyrido[1,2-a]-pyrimidin-4-one, PI 3-K Inhibitor VI
assay
≥97% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white
solubility
DMSO: 10 mg/mL, ethanol: 5 mg/mL
shipped in
ambient
Quality Level
General description
A cell-permeable morpholino-pyrimidinone compound that acts as a reversible, ATP-competitive, selective, and highly potent inhibitor of PI 3-Kβ (IC50 = 0.005, 0.1, 5, and ≥3.5 µM for -β, -δ, -α and -γ isoforms, respectively) with little activity against a panel of 15 commonly studied protein kinases even at concentrations as high as 10.0 µM. An excellent tool for studying p110β-dependent responses both in cells in vitro and in animals in vivo.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PI 3-Kβ
PI 3-Kβ
Product competes with ATP.
Reversible: yes
Target IC50: 0.005, 0.1, 5, and ≥3.5 µM for -β, -δ, -α and -γ isoforms, respectively
Packaging
Packaged under inert gas
Other Notes
Chaussade, C., et al. 2007. Biochem. J.404, 449.
Cosemans, J.M, et al. 2006. Blood108, 3045.
Condliffe, A.M., et al. 2005. Blood106, 1432.
Jackson, S.P., et al. 2005. Nat. Med.11, 507.
Cosemans, J.M, et al. 2006. Blood108, 3045.
Condliffe, A.M., et al. 2005. Blood106, 1432.
Jackson, S.P., et al. 2005. Nat. Med.11, 507.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Kubra Narci et al.
BMC cancer, 22(1), 320-320 (2022-03-26)
Targeted therapies for Primary liver cancer (HCC) is limited to the multi-kinase inhibitors, and not fully effective due to the resistance to these agents because of the heterogeneous molecular nature of HCC developed during chronic liver disease stages and cirrhosis.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持